Determination of candesartan cilexetil, candesartan and a metabolite in human plasma and urine by liquid chromatography and fluorometric detection

J Chromatogr B Biomed Sci Appl. 1999 Aug 20;731(2):411-7. doi: 10.1016/s0378-4347(99)00247-9.

Abstract

Liquid chromatographic methods are described for the determination of a new effective anti-hypertensive drug candesartan (CV-11974), its prodrug candesartan cilexetil (TCV-116) and a metabolite, CV-15959 in human plasma and urine. The assays comprise liquid-liquid extraction and separation on a phenyl column with fluorometric detection. The methods give absolute recoveries of 70, 83 and 78% for candesartan cilexetil, candesartan and CV-15959, respectively, and the limit of quantification is 5, 1 and 3 nM of plasma (RSD < 20%), respectively. The methods were applied to plasma and urine samples from biopharmaceutical and clinical studies in man.

MeSH terms

  • Antihypertensive Agents / blood
  • Antihypertensive Agents / pharmacokinetics
  • Antihypertensive Agents / urine
  • Benzimidazoles / blood
  • Benzimidazoles / pharmacokinetics*
  • Benzimidazoles / urine
  • Biphenyl Compounds / blood
  • Biphenyl Compounds / pharmacokinetics*
  • Biphenyl Compounds / urine
  • Chromatography, Liquid / methods*
  • Humans
  • Prodrugs / pharmacokinetics
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Spectrometry, Fluorescence
  • Tetrazoles / blood
  • Tetrazoles / pharmacokinetics*
  • Tetrazoles / urine

Substances

  • Antihypertensive Agents
  • Benzimidazoles
  • Biphenyl Compounds
  • Prodrugs
  • Tetrazoles
  • candesartan cilexetil
  • candesartan